Evidence map›Paper›PMID 38862744›Full record

ArticleJournal of artificial organs : the official journal of the Japanese Society for Artificial Organs2025

A case of destination therapy for post-fulminant myocarditis with myelodysplastic syndrome.

Makiko Nakamura, Teruhiko Imamura, Yuki Hida, Toshihide Izumida, Masaki Nakagaito, Saori Nagura, Toshio Doi, Kazuaki Fukahara, Koichiro Kinugawa

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Makiko NakamuraThe Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama, Toyama, 930-0194, Japan.
Teruhiko ImamuraThe Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama, Toyama, 930-0194, Japan. teimamu@med.u-toyama.ac.jp.ORCID http://orcid.org/0000-0002-7294-7637
Yuki HidaThe Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama, Toyama, 930-0194, Japan.
Toshihide IzumidaThe Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama, Toyama, 930-0194, Japan.
Masaki NakagaitoThe Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama, Toyama, 930-0194, Japan.
Saori NaguraDepartment of Cardiovascular Surgery, University of Toyama, Toyama, Toyama, Japan.
Toshio DoiDepartment of Cardiovascular Surgery, University of Toyama, Toyama, Toyama, Japan.
Kazuaki FukaharaDepartment of Cardiovascular Surgery, University of Toyama, Toyama, Toyama, Japan.
Koichiro KinugawaThe Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama, Toyama, 930-0194, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We encountered a 64-year-old woman who experienced fulminant myocarditis and underwent treatment with veno-arterial extracorporeal membrane oxygenation and Impella CP support. Subsequently, she underwent a device upgrade to Impella 5.5 and received continuous hemodiafiltration for 3 months. During mechanical circulatory support, she developed refractory anemia and thrombocytopenia, leading to a diagnosis of myelodysplastic syndrome. Following the removal of the devices, she no longer required blood transfusions. She received HeartMate 3 left ventricular assist device implantation as a destination therapy indication despite the presence of myelodysplastic syndrome. She was successfully managed by aspirin-free antithrombotic therapy without any hemocompatibility-related adverse events for 4 months after index discharge on foot. We present a patient with a unique and rare presentation, wherein HeartMate 3 was implanted and successfully managed without aspirin to prevent bleeding complications associated with myelodysplastic syndrome.

Indexed as

Heart-Assist DevicesMyelodysplastic SyndromesMyocarditisShock, CardiogenicThrombosisEchocardiographyExtracorporeal Membrane OxygenationFemaleFibrinolytic AgentsHemorrhageHumansTreatment OutcomeFibrinolytic AgentsCardiogenic shockHemocompatibilityLeft ventricular assist deviceMDS

Identifiers

PMID38862744

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.